OncoZenge AB
8LY
Company Profile
Business description
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
Contact
Gustavslundsvagen 34
Bromma167 51
SWESector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1
Stocks News & Analysis
stocks
Unwarranted drop in ASX share
Jittery investors misinterpret an audit for an existential crisis.
stocks
After earnings, is Disney stock a buy, a sell, or fairly valued? -
Following the highly anticipated announcement of a new CEO, here’s what we think of Disney.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.80 | 97.30 | 1.06% |
| CAC 40 | 8,277.96 | 49.92 | -0.60% |
| DAX 40 | 24,899.33 | 88.52 | -0.35% |
| Dow JONES (US) | 50,135.87 | 20.20 | 0.04% |
| FTSE 100 | 10,383.80 | 29.96 | 0.29% |
| HKSE | 27,266.38 | 83.23 | 0.31% |
| NASDAQ | 23,102.47 | 71.26 | 0.31% |
| Nikkei 225 | 57,699.09 | 1,335.15 | 2.37% |
| NZX 50 Index | 13,507.28 | 60.91 | 0.45% |
| S&P 500 | 6,964.82 | 32.52 | 0.47% |
| S&P/ASX 200 | 9,014.80 | 98.80 | 1.11% |
| SSE Composite Index | 4,131.98 | 3.61 | 0.09% |